Unipi Team Leader: prof. Piero Marchetti, Dip. di Medicina Clinica e Sperimentale
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment. To address these goals, RHAPSODY will bring together prominent European experts, including several leaders of the diabetes-relevant IMI1 projects to identify, validate and characterize causal biomarkers for T2D subtypes and progression.
Our plans are built upon:
- access to large European cohorts with comprehensive genetic analyses and rich longitudinal clinical and biochemical data and samples;
- detailed multi-omic maps of key T2D-relevant tissues and organs;
- large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches;
- the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine; and
- expertise in regulatory approval, health economics and patient engagement.
These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.
Coordinator
UNIVERSITE DE LAUSANNE Switzerland
Participants
- LUNDS UNIVERSITET Sweden
- TECHNISCHE UNIVERSITAET DRESDEN Germany
- UNIVERSITA DI PISA Italy
- UNIVERSITE PARIS DIDEROT - PARIS 7 France
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France
- UNIVERSITE LIBRE DE BRUXELLES Belgium
- SIB INSTITUT SUISSE DE BIOINFORMATIQUE Switzerland
- THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD United Kingdom
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS France
- ITA-SUOMEN YLIOPISTO Finland
- UNIVERSITY OF DUNDEE United Kingdom
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE United Kingdom
- EBERHARD KARLS UNIVERSITAET TUEBINGEN Germany
- LIPOTYPE Germany
- KOBENHAVNS UNIVERSITET Denmark
- AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO Italy
- ACADEMISCH ZIEKENHUIS GRONINGEN Netherlands
- CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE France
- ACADEMISCH ZIEKENHUIS LEIDE NNetherlands
- SCIPROM Sàrl Switzerland
- INSTITUT DE RECHERCHES SERVIER France
- JANSSEN PHARMACEUTICA NV Belgium
- NOVO NORDISK A/S Denmark
- SANOFI-AVENTIS DEUTSCHLAND GMBH Germany
- STICHTING VUMC Netherlands
Start date 01/04/2016
End date 31/03/2020
Duration 48 months
Project cost 15.618.674 €
Project funding 8.130.000 €
Unipi quota 389.043 €
Call title H2020-JTI-IMI2-2015-03-two-stage
Unipi role Participant
Project website https://www.imi-rhapsody.eu/